AbbVie Inc. (ABBV) on Tuesday reported positive topline results from the Phase 3b/4 head-to-head SELECT-SWITCH study, showing that Rinvoq outperformed Humira in treating adults with moderate to severe rheumatoid arthritis.
The study met its primary endpoint, with Rinvoq demonstrating superiority over Humira in achieving low disease activity. About 43.3% of patients receiving Rinvoq achieved low disease activity compared with 22.4% of those on Humira, while both treatments showed no new safety concerns during the 12-week period.
AbbVie shares were up more than 1% in pre-market trading after closing at $197.38 on Monday.
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.